ArcGIS.
Johns
Hopkins University. Retrieved 30 June 2020.
Cui, S., Chen, S., Li, X., Liu, S., and Wang, F. (2020). Prevalence of
venous thromboembolism in patients with severe novel coronavirus
pneumonia. J. Thromb. Haemost.
Dal Moro, F., and Livi, U. (2020). Any possible role of
phosphodiesterase type 5 inhibitors in the treatment of severe COVID19
infections? A lesson from urology. Clin. Immunol. 214 : 108414.
Dallan, C., Romano, F., Siebert, J., Politi, S., Lacroix, L., and
Sahyoun, C. (2020). Septic shock presentation in adolescents with
COVID-19. Lancet Child Adolesc. Heal.
Dastan, F., Nadji, S.A., Saffaei, A., and Tabarsi, P. (2020).
Tocilizumab administration in a refractory case of COVID-19. Int. J.
Antimicrob. Agents 106043 :.
Didangelos, A. (2020). Neutrophil involvement in Covid-19. Preprints.
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J.,
Biondi-Zoccai, G., et al. (2020). Cardiovascular Considerations for
Patients, Health Care Workers, and Health Systems During the COVID-19
Pandemic. J. Am. Coll. Cardiol. 75 : 2352–2371.
Dunkern, T.R., Feurstein, D., Rossi, G.A., Sabatini, F., and Hatzelmann,
A. (2007). Inhibition of TGF-β induced lung fibroblast to myofibroblast
conversion by phosphodiesterase inhibiting drugs and activators of
soluble guanylyl cyclase. Eur. J. Pharmacol. 572 : 12–22.
Dunne, A.E., Kawamatawong, T., Fenwick, P.S., Davies, C.M., Tullett, H.,
Barnes, P.J., et al. (2019). Direct Inhibitory Effect of the PDE4
Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive
Pulmonary Disease. Am. J. Respir. Cell Mol. Biol. 60 : 445–453.
Dusser, D.J., Djokic, T.D., Borson, D.B., and Nadel, J.A. (1989).
Cigarette smoke induces bronchoconstrictor hyperresponsiveness to
substance P and inactivates airway neutral endopeptidase in the guinea
pig. Possible role of free radicals. J. Clin. Invest. 84 :
900–906.
El-Sayed, N.S., and Bayan, Y. (2015). Possible role of Resveratrol
targeting Estradiol and Neprilysin pathways in Lipopolysaccharide model
of Alzheimer disease. Adv. Exp. Med. Biol. 822 : 107–118.
Elshazly, M., Hosny, H., Abdel-Hafiz, H., Zakaria, A., Elkaffas, K., and
Okasha, N. (2013). Assessment of endothelial dysfunction in idiopathic
pulmonary fibrosis. Egypt. J. Chest Dis. Tuberc. 62 : 589–592.
Feng, H., Chen, J., Wang, H., Cheng, Y., Zou, Z., Zhong, Q., et al.
(2017). Roflumilast reverses polymicrobial sepsis-induced liver damage
by inhibiting inflammation in mice. Lab. Investig. 97 :
1008–1019.
Fertig, Bracy A., and G.S.B. (2018). PDE4-Mediated cAMP Signalling. J.
Cardiovasc. Dev. Dis. 5 : 8.
Fitzgerald, M.F., Spicer, D., McAulay, A.E., Wollin, L., and Beume, R.
(2006). Roflumilast but not methylprednisolone inhibited cigarette
smoke-induced pulmonary inflammation in guinea pigs. Eur. Respir. J.
Suppl.
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., and Santoro, A.
(2018). Inflammaging: a new immune–metabolic viewpoint for age-related
diseases. Nat. Rev. Endocrinol. 14 : 576–590.
Fu, B., Xu, X., and Wei, H. (2020). Why tocilizumab could be an
effective treatment for severe COVID-19? J. Transl. Med. 18 : 164.
Fuchs, T.A., Brill, A., Duerschmied, D., Schatzberg, D., Monestier, M.,
Myers, D.D.J., et al. (2010). Extracellular DNA traps promote
thrombosis. Proc. Natl. Acad. Sci. U. S. A. 107 : 15880–15885.
Fukakusa, M., Bergeron, C., Tulic, M.K., Fiset, P.O., Dewachi, O. Al,
Laviolette, M., et al. (2005). Oral corticosteroids decrease eosinophil
and CC chemokine expression but increase neutrophil, IL-8, and
IFN-γ-inducible protein 10 expression in asthmatic airway mucosa. J.
Allergy Clin. Immunol. 115 : 280–286.
Funakoshi, Y., Ichiki, T., Ito, K., and Takeshita, A. (1999). Induction
of interleukin-6 expression by angiotensin II in rat vascular smooth
muscle cells. Hypertension 34 : 118–125.
Gauvreau, G.M., Boulet, L.P., Schmid-Wirlitsch, C., Côté, J., Duong,
M.L., Killian, K.J., et al. (2011). Roflumilast attenuates
allergen-induced inflammation in mild asthmatic subjects. Respir. Res.12 : 140.
Gentile, F., Raptis, A., Knipling, L.G., and Wolff, J. (1988).
Extracellular cAMP formation from host cell ATP by Bordetella pertussis
adenylate cyclase. BBA - Mol. Cell Res. 971 : 63–71.
George, P.M., Wells, A.U., and Jenkins, R.G. (2020). Pulmonary fibrosis
and COVID-19: the potential role for antifibrotic therapy. Lancet
Respir. Med.
Gérard, A., Romani, S., Fresse, A., Viard, D., Parassol, N.,
Granvuillemin, A., et al. (2020). “Off-label” use of
hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in
COVID-19: A survey of cardiac adverse drug reactions by the French
Network of Pharmacovigilance Centers. Therapies.
Gernez, Y., Tirouvanziam, R., and Chanez, P. (2010). Neutrophils in
chronic inflammatory airway diseases: Can we target them and how? Eur.
Respir. J. 35 : 467–469.
Ghasemi, H. (2018). Roles of IL-6 in Ocular Inflammation: A Review.
Ocul. Immunol. Inflamm. 26 : 37–50.
Graf, K., Kunkel, K., Zhang, M., Gräfe, M., Schultz, K., Schudt, C., et
al. (1995). Activation of adenylate cyclase and phosphodiesterase
inhibition enhance neutral endopeptidase activity in human endothelial
cells. Peptides 16 : 1273–1278.
Growcott, E.J., Spink, K.G., Ren, X., Afzal, S., Banner, K.H., and
Wharton, J. (2006). Phosphodiesterase type 4 expression and
anti-proliferative effects in human pulmonary artery smooth muscle
cells. Respir. Res. 7 :.
Gupta, P., and O’Mahony, M.S. (2008). Potential adverse effects of
bronchodilators in the treatment of airways obstruction in older people:
Recommendations for prescribing. Drugs and Aging 25 : 415–443.
Halpin, D.M.G. (2008). ABCD of the phosphodiesterase family: interaction
and differential activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis.3 : 543–561.
Hamming, I., Timens, W., Bulthuis, M.L.C., Lely, A.T., Navis, G.J., and
Goor, H. van (2004). Tissue distribution of ACE2 protein, the functional
receptor for SARS coronavirus. A first step in understanding SARS
pathogenesis. J. Pathol. 203 : 631–637.
Harding, S.D., Sharman, J.L., Faccenda, E., Southan, C., Pawson, A.J.,
Ireland, S., et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in
2018: updates and expansion to encompass the new guide to
IMMUNOPHARMACOLOGY. Nucleic Acids Res. 46 : 1091–1106.
Hatzelmann, A., Morcillo, E.J., Lungarella, G., Adnot, S., Sanjar, S.,
Beume, R., et al. (2010). The preclinical pharmacology of roflumilast–a
selective, oral phosphodiesterase 4 inhibitor in development for chronic
obstructive pulmonary disease. Pulm. Pharmacol. Ther. 23 :
235–256.
He, J., Hu, L., Huang, X., Wang, C., Zhang, Z., Wang, Y., et al. (2020).
Potential of coronavirus 3C-like protease inhibitors for the development
of new anti-SARS-CoV-2 drugs: Insights from structures of protease and
inhibitors. Int. J. Antimicrob. Agents 106055.
Henkin, R.I., Schmidt, L., and Velicu, I. (2013). Interleukin 6 in
hyposmia. JAMA Otolaryngol. - Head Neck Surg. 139 : 728–734.
Hertz, A.L., Bender, A.T., Smith, K.C., Gilchrist, M., Amieux, P.S.,
Aderem, A., et al. (2009). Elevated cyclic AMP and PDE4 inhibition
induce chemokine expression in human monocyte-derived macrophages. Proc.
Natl. Acad. Sci. 106 : 21978–21983.
Hu, C., Lu, L., Wan, J.-P., and Wen, C. (2017). The Pharmacological
Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic
and Related Diseases. Curr. Med. Chem. 24 : 2241–2249.
Hu, F., Jiang, J., and Yin, P. (2020). Prediction of potential
commercially inhibitors against SARS-CoV-2 by multi-task deep model.
ArXiv Prepr. 2003.00728 :
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020).
Clinical features of patients infected with 2019 novel coronavirus in
Wuhan, China. Lancet 395 : 497–506.
Hung, M.J., Cherng, W.J., Hung, M.Y., Wu, H.T., and Pang, J.H.S. (2010).
Interleukin-6 inhibits endothelial nitric oxide synthase activation and
increases endothelial nitric oxide synthase binding to stabilized
caveolin-1 in human vascular endothelial cells. J. Hypertens. 28 :
940–951.
Hyun, Y., and Hong, C. (2017). Deep insight into neutrophil trafficking
in various organs. J. Leukoc. Biol. 102 : 617–629.
Insel, P.A., Murray, F., Yokoyama, U., Romano, S., Yun, H., Brown, L.,
et al. (2012). CAMP and Epac in the regulation of tissue fibrosis. Br.
J. Pharmacol. 166 : 447–456.
Isoni, C.A., Borges, É.A., Veloso, C.A., Mattos, R.T., Chaves, M.M., and
Nogueira-Machado, J.A. (2009). cAMP activates the generation of reactive
oxygen species and inhibits the secretion of IL-6 in peripheral blood
mononuclear cells from type 2 diabetic patients. Oxid. Med. Cell.
Longev. 2 : 317–321.
Jacoby, D.B., Tamaoki, J., Borson, D.B., and Nadel, J.A. (1988).
Influenza infection causes airway hyperresponsiveness by decreasing
enkephalinase. J. Appl. Physiol. 64 : 2653–2658.
Jia, H. (2016). Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and
Inflammatory Lung Disease. Shock 46 : 239–248.
Jin, J.-M., Bai, P., He, W., Wu, F., Liu, X.-F., Han, D.-M., et al.
(2020). Gender Differences in Patients With COVID-19: Focus on Severity
and Mortality. Front. Public Heal. 8 : 152.
Jones, N.A., Boswell-Smith, V., Lever, R., and Page, C.P. (2005). The
effect of selective phosphodiesterase isoenzyme inhibition on neutrophil
function in vitro. Pulm. Pharmacol. Ther. 18 : 93–101.
Joyce, E., Fabre, A., and Mahon, N. (2013). Hydroxychloroquine
cardiotoxicity presenting as a rapidly evolving biventricular
cardiomyopathy: Key diagnostic features and literature review. Eur.
Hear. J. Acute Cardiovasc. Care 2 : 77–83.
Kassi, E., and Moutsatsou, P. (2010). Estrogen Receptor Signaling and
Its Relationship to Cytokines in Systemic Lupus Erythematosus. J.
Biomed. Biotechnol.
Kawamatawong, T. (2017). Roles of roflumilast, a selective
phosphodiesterase 4 inhibitor, in airway diseases. J. Thorac. Dis.9 : 1144.
Kell, D.B., Heyden, E.L., and Pretorius, E. (2020). The Biology of
Lactoferrin, an Iron-Binding Protein That Can Help Defend Against
Viruses and Bacteria. Front. Immunol. 11 : 1221.
Kimball, A.S., Obi, A.T., Diaz, J.A., and Henke, P.K. (2016). The
Emerging Role of NETs in Venous Thrombosis and Immunothrombosis. Front.
Immunol. 7 : 236.
Kletsas, D., Caselgrandi, E., Barbieri, D., Stathakos, D., Franceschi,
C., and Ottaviani, E. (1998). Neutral endopeptidase-24.11 (NEP) activity
in human fibroblasts during development and ageing. Mech. Ageing Dev.102 : 15–23.
Klok, F.A., Kruip, M.J.H.A., Meer, N.J.M. van der, Arbous, M.S.,
Gommers, D.A.M.P.J., Kant, K.M., et al. (2020). Incidence of thrombotic
complications in critically ill ICU patients with COVID-19. Thromb. Res.
Kowalczyk, A., Kleniewska, P., Kolodziejczyk, M., Skibska, B., and
Goraca, A. (2015). The role of endothelin-1 and endothelin receptor
antagonists in inflammatory response and sepsis. Arch. Immunol. Ther.
Exp. (Warsz). 63 : 41–52.
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., et al. (2005).
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS
coronavirus-induced lung injury. Nat. Med. 11 : 875–879.
Kumar, N., Goldminz, A.M., Kim, N., and Gottlieb, A.B. (2013).
Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC
Med. 11 : 96.
Kumar, R.K., Herbert, C., Thomas, P.S., Wollin, L., Beume, R., Yang, M.,
et al. (2003). Inhibition of inflammation and remodeling by roflumilast
and dexamethasone in murine chronic asthma. J. Pharmacol. Exp. Ther.307 : 349–355.
Lai, C.C., Liu, Y.H., Wang, C.Y., Wang, Y.H., Hsueh, S.C., Yen, M.Y., et
al. (2020). Asymptomatic carrier state, acute respiratory disease, and
pneumonia due to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2): Facts and myths. J. Microbiol. Immunol. Infect. 53 :
404.
Leonard-Lorant, I., Delabranche, X., Severac, F., Helms, J., Pauzet, C.,
Collange, O., et al. (2020). Acute Pulmonary Embolism in COVID-19
Patients on CT Angiography and Relationship to D-Dimer Levels. Radiology
201561.
Levi, M., and Poll, T. van der (2017). Coagulation and sepsis. Thromb.
Res. 149 : 38–44.
Li, C., Booze, R.M., and Hersh, L.B. (1995). Tissue-specific expression
of rat neutral endopeptidase (neprilysin) mRNAs. J. Biol. Chem.270 : 5723–5728.
Li, H., Liu, L., Zhang, D., Xu, J., Dai, H., Tang, N., et al. (2020a).
SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet395 : 1517–1520.
Li, H., Liu, S.M., Yu, X.H., Tang, S.L., and Tang, C.K. (2020b).
Coronavirus disease 2019 (COVID-19): current status and future
perspectives. Int. J. Antimicrob. Agents 55 : 105951.
Li, H., Zuo, J., and Tang, W. (2018). Phosphodiesterase-4 inhibitors for
the treatment of inflammatory diseases. Front. Pharmacol. 9 :.
Liu, H., Wang, L.L., Zhao, S.J., Kwak-Kim, J., Mor, G., and Liao, A.H.
(2020a). Why are pregnant women susceptible to COVID-19? An
immunological viewpoint. J. Reprod. Immunol. 139 : 103122.
Liu, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J., et al. (2020b).
The potential role of IL-6 in monitoring severe case of coronavirus
disease 2019. MedRxiv.
Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., et al.
(2020c). Clinical and biochemical indexes from 2019-nCoV infected
patients linked to viral loads and lung injury. Sci. China Life Sci.63 : 364–374.
Luërs, J.C., Klumann, J.P., and Guntinas-Lichius, O. (2020). The
COVID-19 pandemic and otolaryngology: What it comes down to?
Laryngorhinootologie. 99 : 287–291.
Lyu, J., Miao, T., Dong, J., Cao, R., Li, Y., and Chen, Q. (2020).
Reflection on lower rates of COVID-19 in children: Does childhood
immunizations offer unexpected protection? Med. Hypotheses 143 :
109842.
Malińska, D., Więckowski, M.R., Michalska, B., Drabik, K., Prill, M.,
Patalas-Krawczyk, P., et al. (2019). Mitochondria as a possible target
for nicotine action. J. Bioenerg. Biomembr. 51 : 259–276.
Mantzarlis, K., Tsolaki, V., and Zakynthinos, E. (2017). Role of
Oxidative Stress and Mitochondrial Dysfunction in Sepsis and Potential
Therapies. Oxid. Med. Cell. Longev.
Mao, L., Wang, M., Chen, S., He, Q., Chang, J., Hong, C., et al. (2020).
Neurologic Manifestations of Hospitalized Patients With Coronavirus
Disease 2019 in Wuhan, China. JAMA Neurol. 77 : 683–690.
Maria, G.U. Di, Bellofiore, S., and Geppetti, P. (1998). Regulation of
airway neurogenic inflammation by neutral endopeptidase. Eur. Respir. J.12 : 1454–62.
Marinosci, A., Landis, B.N., and Calmy, A. (2020). Possible link between
anosmia and COVID-19: sniffing out the truth. Eur. Arch.
Oto-Rhino-Laryngology 277 : 2149–2150.
Martinez, F.J., Calverley, P.M.A., Goehring, U.-M., Brose, M., Fabbri,
L.M., and Rabe, K.F. (2015). Effect of roflumilast on exacerbations in
patients with severe chronic obstructive pulmonary disease uncontrolled
by combination therapy (REACT): a multicentre randomised controlled
trial. Lancet 385 : 857–866.
McGonagle, D., O’Donnell, J.S., Sharif, K., Emery, P., and Bridgewood,
C. (2020). Immune mechanisms of pulmonary intravascular coagulopathy in
COVID-19 pneumonia. Lancet Rheumatol.
Mehra, M.R., Desai, S.S., Ruschitzka, F., and Patel, A.N. (2020).
Hydroxychloroquine or chloroquine with or without a macrolide for
treatment of COVID-19: a multinational registry analysis. Lancet.
Meyer-Hoffert, U. (2009). Neutrophil-derived serine proteases modulate
innate immune responses. Front. Biosci. 14 : 3409–3418.
Milara, J., Morcillo, E., Monleon, D., Tenor, H., and Cortijo, J.
(2015a). Roflumilast prevents the metabolic effects of bleomycin-induced
fibrosis in a murine model. PLoS One 10 : e0133453.
Milara, J., Morell, A., Ballester, B., Sanz, C., Freire, J., Qian, X.,
et al. (2015b). Roflumilast improves corticosteroid resistance COPD
bronchial epithelial cells stimulated with toll like receptor 3 agonist.
Respir. Res. 16 : 12.
Milara, J., Peiro, T., Serrano, A., Artigues, E., Aparicio, J., Tenor,
H., et al. (2015c). Simvastatin increases the ability of roflumilast
N-oxide to inhibit cigarette smoke-induced epithelial to mesenchymal
transition in well-differentiated human bronchial epithelial cells in
vitro. COPD J. Chronic Obstr. Pulm. Dis. 12 : 327–338.
Molano Franco, D., Arevalo-Rodriguez, I., Roqué I Figuls, M., Montero
Oleas, N.G., Nuvials, X., and Zamora, J. (2019). Plasma interleukin-6
concentration for the diagnosis of sepsis in critically ill adults.
Cochrane Database Syst. Rev. 4 : CD011811.
Mudter, J., and Neurath, M.F. (2007). Il-6 signaling in inflammatory
bowel disease: Pathophysiological role and clinical relevance. Inflamm.
Bowel Dis. 13 : 1016–1023.
Muo, I.M., MacDonald, S.D., Madan, R., Park, S.-J., Gharib, A.M.,
Martinez, P.E., et al. (2019). Early effects of roflumilast on insulin
sensitivity in adults with prediabetes and overweight/obesity involve
age-associated fat mass loss–results of an exploratory study. Diabetes,
Metab. Syndr. Obes. Targets Ther. 12 : 743.
Mustafa, S.B., Gandhi, C.R., Harvey, S.A.K., and Olson, M.S. (1995).
Endothelin stimulates platelet-activating factor synthesis by cultured
rat kupffer cells. Hepatology 21 : 545–553.
Owa, A.B., and Owa, O.T. (2020). Lopinavir/ritonavir use in Covid-19
infection: is it completely non-beneficial? J. Microbiol. Immunol.
Infect.
Pani, A., Lauriola, M., Romandini, A., and Scaglione, F. (2020).
Macrolides and viral infections: focus on azithromycin in COVID-19
pathology. Int. J. Antimicrob. Agents 106053.
Patel, B.S., Rahman, M.M., Baehring, G., Xenaki, D., Tang, F.S.-M.,
Oliver, B.G., et al. (2017). Roflumilast N-oxide in combination with
formoterol enhances the antiinflammatory effect of dexamethasone in
airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 56 :
532–538.
Pham, C.T.N. (2006). Neutrophil serine proteases: Specific regulators of
inflammation. Nat. Rev. Immunol. 6 : 541–550.
Press, N.J., and Banner, K.H. (2009). 2 PDE4 Inhibitors - A Review of
the Current Field. Prog. Med. Chem. 47 : 37–74.
Rabe, K.F. (2011). Update on roflumilast, a phosphodiesterase 4
inhibitor for the treatment of chronic obstructive pulmonary disease.
Br. J. Pharmacol. 163 : 53–67.
Rabe, K.F., Watz, H., Baraldo, S., Pedersen, F., Biondini, D., Bagul,
N., et al. (2018). Anti-inflammatory effects of roflumilast in chronic
obstructive pulmonary disease (ROBERT): a 16-week, randomised,
placebo-controlled trial. Lancet Respir. Med. 6 : 827–836.
Raker, V.K., Becker, C., and Steinbrink, K. (2016). The cAMP pathway as
therapeutic target in autoimmune and inflammatory diseases. Front.
Immunol. 7 : 123.
Rao, G.H.R., and White, J.G. (1982). Platelet activating factor (paf)
causes human platelet aggregation through the mechanism of membrane
modulation. Prostaglandins, Leukot. Med. 9 : 459–472.
Rao, V.U., Pavlov, A., Klearman, M., Musselman, D., Giles, J.T., Bathon,
J.M., et al. (2015). An evaluation of risk factors for major adverse
cardiovascular events during tocilizumab therapy. Arthritis Rheumatol.67 : 372–380.
Rasmo, D. De, Micelli, L., Santeramo, A., Signorile, A., Lattanzio, P.,
and Papa, S. (2016). CAMP regulates the functional activity, coupling
efficiency and structural organization of mammalian FOF1 ATP synthase.
Biochim. Biophys. Acta - Bioenerg. 1857 : 350–358.
Reddy, A.T., Lakshmi, S.P., Banno, A., and Reddy, R.C. (2020).
Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore
Dexamethasone Sensitivity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis.15 : 125–134.
Redford, P.S., Murray, P.J., and O’garra, A. (2011). The role of IL-10
in immune regulation during M. tuberculosis infection. Mucosal Immunol.4 : 261–270.
Remy, K.E., Brakenridge, S.C., Francois, B., Daix, T., Deutschman, C.S.,
Monneret, G., et al. (2020). Immunotherapies for COVID-19: lessons
learned from sepsis. Lancet. Respir. Med.
Rhee, C.K., and Kim, D.K. (2020). Role of phosphodiesterase-4 inhibitors
in chronic obstructive pulmonary disease. Korean J. Intern. Med.35 : 276–283.
Rosenberg, E.S., Dufort, E.M., Udo, T., Wilberschied, L.A., Kumar, J.,
Tesoriero, J., et al. (2020). Association of Treatment with
Hydroxychloroquine or Azithromycin with In-Hospital Mortality in
Patients with COVID-19 in New York State. JAMA - J. Am. Med. Assoc.
Sanz, M.J., Cortijo, J., Taha, M.A., Cerdá-Nicolás, M., Schatton, E.,
Burgbacher, B., et al. (2007). Roflumilast inhibits
leukocyte-endothelial cell interactions, expression of adhesion
molecules and microvascular permeability. Br. J. Pharmacol. 152 :
481–492.
Sato, T., Hongu, T., Sakamoto, M., Funakoshi, Y., and Kanaho, Y. (2013).
Molecular Mechanisms of N-Formyl-Methionyl-Leucyl-Phenylalanine-Induced
Superoxide Generation and Degranulation in Mouse Neutrophils:
Phospholipase D Is Dispensable. Mol. Cell. Biol. 33 : 136–145.
Schalkwyk, E. van, Strydom, K., Williams, Z., Venter, L., Leichtl, S.,
Schmid-Wirlitsch, C., et al. (2005). Roflumilast, an oral, once-daily
phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic
reactions. J. Allergy Clin. Immunol. 116 : 292–298.
Schouten, M., Wiersinga, W.J., Levi, M., and Poll, T. van der (2008).
Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol.83 : 536–545.
Shames, B.D., McIntyre, R.C., Bensard, D.D., Pulido, E.J., Selzman,
C.H., Reznikov, L.L., et al. (2001). Suppression of tumor necrosis
factor α production by cAMP in human monocytes: Dissociation with mRNA
level and independent of interleukin-10. J. Surg. Res. 99 :
187–193.
Shen, L.-F., Lv, X.-D., Chen, W.-Y., Yang, Q., Fang, Z.-X., and Lu,
W.-F. (2018). Effect of roflumilast on chronic obstructive pulmonary
disease: a systematic review and meta-analysis. Ir. J. Med. Sci.187 : 731–738.
Shimamoto, K., Ura, N., and Iimura, O. (1994). The natriuretic
mechanisms of neutral endopeptidase inhibitor in rats. Brazilian J. Med.
Biol. Res. Rev. Bras. Pesqui. Medicas e Biol. 27 : 1965–1973.
Silva, S., Amarasena, R., Moorcroft, J., Rajakulenthiran, T., and Singh,
R. (2020). Tocilizumab-induced pulmonary fibrosis in a patient with
rheumatoid arthritis. Clin. Med. (Northfield. Il). 20 : s57–s57.
Singhal, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19).
Indian J. Pediatr. 87 : 281–286.
Song, Y., Liu, P., Shi, X.L., Chu, Y.L., Zhang, J., Xia, J., et al.
(2020). SARS-CoV-2 induced diarrhoea as onset symptom in patient with
COVID-19. Gut 69 : 1143–1144.
Sont, J.K., Krieken, J.H.J.M. Van, Klink, H.C.J. Van, Roldaan, A.C.,
Apap, C.R., Willems, L.N.A., et al. (1997). Enhanced Expression of
Neutral Endopeptidase (NEP) in Airway Epithelium in Biopsies from
Steroid- versus Nonsteroid-treated Patients with Atopic Asthma. Am. J.
Respir. Cell Mol. Biol. 16 : 549–556.
Sprague, A.H., and Khalil, R.A. (2009). Inflammatory cytokines in
vascular dysfunction and vascular disease. Biochem. Pharmacol.78 : 539–552.
Srivastava, S. (2017). The mitochondrial basis of aging and age-related
disorders. Genes (Basel). 8 : 398.
Tabaa, M.M. El, and Tabaa, M.M. El (2020). Targeting Neprilysin (NEP)
pathways: A potential new hope to defeat COVID-19 ghost. Biochem.
Pharmacol. 114057.
Taghizadeh-Hesary, F., and Akbari, H. (2020). The powerful immune system
against powerful COVID-19: A hypothesis. Med. Hypotheses 140 :
109762.
Tamara, A., and Tahapary, D.L. (2020). Obesity as a predictor for a poor
prognosis of COVID-19: A systematic review. Diabetes Metab. Syndr. Clin.
Res. Rev. 14 : 655–659.
Tay, M.Z., Poh, C.M., Rénia, L., MacAry, P.A., and Ng, L.F.P. (2020).
The trinity of COVID-19: immunity, inflammation and intervention. Nat.
Rev. Immunol. 20 : 363–374.
Tenor, H., Hatzelmann, A., Church, M.K., Schudt, C., and Shute, J.K.
(1996). Effects of theophylline and rolipram on leukotriene C4 (LTC4)
synthesis and chemotaxis of human eosinophils from normal and atopic
subjects. Br. J. Pharmacol. 118 : 1727–1735.
Togo, S., Liu, X., Wang, X., Sugiura, H., Kamio, K., Kawasaki, S., et
al. (2009). PDE4 inhibitors roflumilast and rolipram augment PGE2
inhibition of TGF-β1-stimulated fibroblasts. Am. J. Physiol. - Lung
Cell. Mol. Physiol. 296 : L959-69.
Totani, L., Amore, C., Santo, A. Di, Dell’Elba, G., Piccoli, A.,
Martelli, N., et al. (2016). Roflumilast inhibits leukocyte–platelet
interactions and prevents the prothrombotic functions of
polymorphonuclear leukocytes and monocytes. J. Thromb. Haemost.14 : 191–204.
Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R.,
Zinkernagel, A.S., et al. (2020). Endothelial cell infection and
endotheliitis in COVID-19. Lancet 395 : 1417–1418.
Vishnevetsky, A., and Levy, M. (2020). Rethinking high-risk groups in
COVID-19. Mult. Scler. Relat. Disord. 42 : 102139.
Vollert, S., Kaessner, N., Heuser, A., Hanauer, G., Dieckmann, A.,
Knaack, D., et al. (2012). The glucose-lowering effects of the PDE4
inhibitors roflumilast and roflumilast-N-oxide in db/db mice.
Diabetologia 55 : 2779–2788.
Wang, M., Gao, P., Wu, X., Chen, Y., Feng, Y., Yang, Q., et al. (2016).
Impaired anti-inflammatory action of glucocorticoid in neutrophil from
patients with steroid-resistant asthma. Respir. Res. 17 : 1–9.
Weiss, B., and Hait, W.N. (1977). Selective cyclic nucleotide
phosphodiesterase inhibitors as potential therapeutic agents. Annu. Rev.
Pharmacol. Toxicol. 17 : 441–477.
Wermuth, P.J., Li, Z., Mendoza, F.A., and Jimenez, S.A. (2016).
Stimulation of Transforming Growth Factor-β1-Induced
Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by
Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1. PLoS One11 : e0161988.
Westphal, J.F. (2000). Macrolide - Induced clinically relevant drug
interactions with cytochrome P-450A (CYP) 3A4: An update focused on
clarithromycin, azithromycin and dirithromycin. Br. J. Clin. Pharmacol.50 : 285–295.
Wick, M.J., Buesing, E.J., Wehling, C.A., Loomis, Z.L., Cool, C.D.,
Zamora, M.R., et al. (2011). Decreased neprilysin and pulmonary vascular
remodeling in chronic obstructive pulmonary disease. Am. J. Respir.
Crit. Care Med. 183 : 330–340.
Wintroub, B.U., Schechter, N.B., Lazarus, G.S., Kaempfer, C.E., and
Schwartz, L.B. (1984). Angiotensin I conversion by human and rat
chymotryptic proteinases. J. Invest. Dermatol. 83 : 336–339.
Wouters, E.F.M., Bredenbröker, D., Teichmann, P., Brose, M., Rabe, K.F.,
Fabbri, L.M., et al. (2012). Effect of the phosphodiesterase 4 inhibitor
roflumilast on glucose metabolism in patients with treatment-naive,
newly diagnosed type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.97 : E1720–E1725.
Wu, P., Duan, F., Luo, C., Liu, Q., Qu, X., Liang, L., et al. (2020).
Characteristics of Ocular Findings of Patients with Coronavirus Disease
2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 138 :
575–578.
Xiao, Z.M., Sun, L., Liu, Y.M., Zhang, J.J., and Huang, J. (2009).
Estrogen regulation of the neprilysin gene through a hormone-responsive
element. J. Mol. Neurosci. 39 : 22–26.
Xiong, Y., Liu, Y., Cao, L., Wang, D., Guo, M., Jiang, A., et al.
(2020). Transcriptomic characteristics of bronchoalveolar lavage fluid
and peripheral blood mononuclear cells in COVID-19 patients. Emerg.
Microbes Infect. 9 : 761–770.
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., et al. (2020).
Clinical course and outcomes of critically ill patients with SARS-CoV-2
pneumonia in Wuhan, China: a single-centered, retrospective,
observational study. Lancet Respir. Med. 8 : 475–481.
Yao, M., Nguyen, T.V. V., Rosario, E.R., Ramsden, M., and Pike, C.J.
(2008). Androgens regulate neprilysin expression: Role in reducing
β-amyloid levels. J. Neurochem. 105 : 2477–2488.
Zhang, H., Penninger, J.M., Li, Y., Zhong, N., and Slutsky, A.S.
(2020a). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2
receptor: molecular mechanisms and potential therapeutic target.
Intensive Care Med. 46 : 586–590.
Zhang, Y., Geng, X., Tan, Y., Li, Q., Xu, C., Xu, J., et al. (2020b).
New understanding of the damage of SARS-CoV-2 infection outside the
respiratory system. Biomed. Pharmacother. 127 : 110195.
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al. (2020).
Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet395 : 1054–1062.
Ziebuhr, J. (2005). The coronavirus replicase. Curr. Top. Microbiol.
Immunol. 287 : 57–94.
Zuo, Y., Zuo, M., Yalavarthi, S., Gockman, K., Madison, J.A., Shi, H.,
et al. Neutrophil extracellular traps and thrombosis in COVID-19.
MedRxiv.
Zyl-Smit, R.N. van, Richards, G., and Leone, F.T. (2020). Tobacco
smoking and COVID-19 infection. Lancet Respir. Med. 1451–1454.
Table 1: Multiple pharmacological properties of
roflumilast.